Predicting clinical progression trajectories of early Alzheimer's disease patients
Alzheimer's & Dementia · 2024-03 · 20 (3) · 1725-1738
DOI: 10.1002/alz.13565 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 13.12.2023. Verfasst von Viswanath Devanarayan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Evidence Generation, Eisai Inc., Nutley, New Jersey, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, CIHR, NIBIB NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
BACKGROUND Models for forecasting individual clinical progression trajectories in early Alzheimer's disease (AD) are needed for optimizing clinical studies and patient monitoring. METHODS Prediction models were constructed using a clinical trial training cohort (TC; n = 934) via a gradient boosting algorithm and then evaluated in two validation cohorts (VC 1, n = 235; VC 2, n = 421). Model inputs included baseline clinical features (cognitive function assessments, APOE ε4 status, and demographics) and brain magnetic resonance imaging (MRI) measures. RESULTS The model using clinical features achieved R 2 of 0.21 and 0.31 for predicting 2‐year cognitive decline in VC 1 and VC 2, respectively. Adding MRI features improved the R 2 to 0.29 in VC 1, which employed the same preprocessing pipeline as the TC. Utilizing these model‐based predictions for clinical trial enrichment reduced the required sample size by 20% to 49%. DISCUSSION Our validated prediction models enable baseline prediction of clinical progression trajectories in early AD, benefiting clinical trial enrichment and various applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Evidence Generation, Eisai Inc., Nutley, New Jersey, USA.
- Department of Mathematics, Statistics and Computer Science, University of Illinois Chicago, Chicago, Illinois, USA.
- Carle Illinois College of Medicine, Urbana, Illinois, USA.
- Department of Molecular and Integrative Physiology, University of Illinois Urbana-Champaign, Urbana, Illinois, USA.
- Department of Biomedical Data Science, Stanford University School of Medicine, Palo Alto, California, USA.
ORCID-Profile: Viswanath Devanarayan
Förderung
- NIA NIH HHS
- CIHR
- NIBIB NIH HHS
- NIH HHS
- Alzheimer's Disease Neuroimaging Initiative
- National Institutes of Health
- U.S. Department of Defense
- National Institute on Aging
Zitieren
APA
Devanarayan, V., Ye, Y., Charil, A., Andreozzi, E., Sachdev, P., Llano, D. A., Tian, L., Zhu, L., Hampel, H., Kramer, L., Dhadda, S., Irizarry, M., & Alzheimer's Disease Neuroimaging Initiative (ADNI) (2024). Predicting clinical progression trajectories of early Alzheimer's disease patients. Alzheimer's & Dementia, 20(3), 1725-1738. https://doi.org/10.1002/alz.13565
Vancouver
Devanarayan V, Ye Y, Charil A, Andreozzi E, Sachdev P, Llano DA, et al. Predicting clinical progression trajectories of early Alzheimer's disease patients. Alzheimer's & Dementia. 2024;20(3):1725-1738. doi:10.1002/alz.13565
BibTeX
@article{Devanarayan2024,
author = {Devanarayan, Viswanath and Ye, Yuanqing and Charil, Arnaud and Andreozzi, Erica and Sachdev, Pallavi and Llano, Daniel A and Tian, Lu and Zhu, Liang and Hampel, Harald and Kramer, Lynn and Dhadda, Shobha and Irizarry, Michael and Alzheimer's Disease Neuroimaging Initiative (ADNI), Alzheimer's Disease Neuroimaging Initiative (ADNI)},
title = {Predicting clinical progression trajectories of early Alzheimer's disease patients},
journal = {Alzheimer's & Dementia},
year = {2024},
volume = {20},
number = {3},
pages = {1725--1738},
doi = {10.1002/alz.13565}
}
EUVIMED